摘要
目的比较莫西沙星和常用的经验性抗生素治疗社区获得性肺炎（CAP）的有效性和安全性。方法40例需住院的CAP患者随机分为莫西沙星组（20例）和对照组（头孢哌酮＋阿奇霉素20例），疗程7～14d。治疗前后进行临床实验室检查对比。结果莫西沙星针剂治疗CAP患者的临床疗效和细菌清除与对照组相同。CAP患者对莫西沙星有较好的耐受性。结论莫西沙星单用可作为CAP的经验性治疗方案。
Objective To compare the efficacy, safety, and tolerability of intravenous moxifloxacin with that of a commonly used empirical antibiotic regimen, cefoperazone and azithromycin in the treatment of community acquired pneumonia in adult patients. Methods 40 patients with CAP were divided into two groups, moxifloxacin group （20 patients） and comparator group （cefoperazone ＋ azithromycin, 20 patients） for 7 to 14 days. Clinical, bacteriological, and laboratory examinations were performed pretreatment, at the end of treatment. Results There was nosiginficant difference in the clinical efficacy rate between two groups at end of therapy. Both study drugs were well tolerated in this trial. Conclusion Moxifloxacin is likely to offer clinicians an alternative for reliable empirical CAP treatment in the face of increasing antibiotic resistance.
出处
《临床肺科杂志》
2006年第6期761-762,共2页
Journal of Clinical Pulmonary Medicine
